GLP-1 Microdosing and Exoskeleton Rehab

Editors’ Note: Week 3 is here! We’ve loved hearing your thoughts, both the praise and the constructive feedback. Please keep it coming!

Thanks to Pique Life for sponsoring today’s issue!

Words in blue will be defined in Today’s Dictionary below!

Drugs like Ozempic, Wegovy, and Zepbound have become household names for their dramatic weight-loss results, celebrity users, and nonstop media coverage. High prices, high doses, and a high chance of stomach side effects have made them as polarizing as they are popular.

Noom released a GLP-1 microdosing plan two weeks ago. The plan uses a maintenance dose of 0.6mg of semaglutide per week, compared to the 2.4mg weekly maintenance dose typical of full-strength weight-loss regimens like Wegovy. GLP-1 is a naturally occurring hormone that plays a role in regulating blood sugar and appetite levels. Semaglutides are a type of GLP-1 drug that reduce appetite and improve blood sugar management.

How it differs from existing plans

Research presented at the American Diabetes Association’s 2025 conference found that up to 40% of the weight lost on standard-dose GLP-1 programs may come from lean mass, which includes muscle. Microdosing will not completely eliminate that risk, but the more gradual change in appetite and fewer side effects make it easier to consume adequate protein and continue strength training. This is a strong option for someone looking to recomp, short for body recomposition, which is the process of reducing fat while maintaining or increasing muscle mass.

The fine print

The medication comes from compounding pharmacies rather than original manufacturers. This is legal under certain conditions but draws scrutiny from the FDA and from companies like Novo Nordisk and Eli Lilly. Early research suggests lower doses can still produce meaningful fat loss and metabolic benefits, yet the durability of these results over years is unknown.

Why you should care

A lower dose does not automatically preserve more muscle mass, but it can give you more opportunity to protect it by making it easier to train consistently and hit your protein targets. Lean mass is the engine for strength, metabolism, and long-term independence. Losing too much of it can mean a lower resting calorie burn, slower recovery from workouts, and reduced power in daily life. Microdosing may not deliver weight loss as quickly as full-dose regimens, yet the trade-off is a pace that better supports muscle maintenance and sustainable habits. Before signing up, individuals should confirm the compounding pharmacy’s credentials, ask how your dose will be adjusted, and check how your health data will be handled.

I used to feel dry, foggy, and drained—until I tried Pique’s Deep Hydration Protocol. This day-to-night electrolyte duo hydrates skin, calms the nervous system, and supports deep sleep. No sugar, no fillers—just results. I feel clear, radiant, and truly hydrated.

Get 20% off for life

Caroline Laubach, 22, hadn’t taken a step since a spinal stroke at 18. A few weeks ago, inside Wandercraft’s Manhattan showroom, she stood, balanced, and walked across the floor in the self-balancing Atalante exoskeleton. At that moment, it looked less like science fiction and more like a wearable weight rack, shifting load back where it used to be.

More Than Mobility

Unlike passive wheelchairs, lower-limb exoskeletons actively load the body. Each guided step reactivates dormant muscle fibers and nerves, spikes metabolic demand, and improves breathing mechanics. A meta-analysis published this spring found robotic gait training improved lower-limb strength and balance in spinal-cord-injured patients more than conventional therapy alone.

Clinics are scaling fast. Ekso Bionics’ EksoNR is a robotic exoskeleton cleared by the FDA. It supports stroke, spinal-cord, acquired brain injury, and multiple sclerosis. Designed as a high-intensity gait-training tool, it supports mobilization and allows therapists to dial assistance up or down in real time, helping retrain the patients’ muscles. Early clinical programs report stronger hip flexors and faster returns to over-ground walking compared to parallel-bar training alone.

Wandercraft’s personal-use model, Eve, is the world’s first self-balance exoskeleton made for home and outdoor use. Clinical trials begin this year at the Bronx VA and Kessler Institute with potential commercialization in 2026. Medicare has already established a reimbursement category for personal exoskeletons, setting allowable payments for comparable devices in the $80,000-$110,000 range with a standard rate of about $91,000. 

Why you should care

After injury or illness, regaining lost muscle and mobility is slow and often incomplete. Exoskeletons restore movement while engaging muscles, applying healthy load to bones, and encouraging the brain and body to relearn walking patterns. That can mean faster rehab, fewer secondary health problems, and greater independence. For clinicians, it could free up beds and shorten waitlists. For families, it offers a chance to bring walking back into daily life. Even if you never need one yourself, the science driving these devices is reshaping the next generation of fitness and rehab tools.

Or copy and paste this link to others: {{rp_refer_url}}

Current Referral Count: {{rp_num_referrals}}